Physician profile
Daniel C Aukerman
NPI 1659494110
$374.69
in general payments reported to CMS, 2019-2025
10 companies · $15.22 in 2025
The $15.22 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.20 · 2020: $34.75 · 2021: $35.63 · 2023: $105 · 2024: $107 · 2025: $15.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $227.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $106.55 | 2024 | Xarelto |
| Indivior INC. | $90.94 | 2020-2023 | Sublocade |
| Alkermes, INC. | $50.68 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $33.90 | 2019 | |
| Orexo US, INC. | $21.07 | 2023 | Zubsolv |
| Novo Nordisk INC | $15.94 | 2023 | Rybelsus, Ozempic |
| Tactile Systems Technology INC | $15.22 | 2025 | Flexitouch Plus, Nimbl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.46 | 2019 | |
| Braeburn INC. | $14.14 | 2023 | Brixadi |
| Uswm, LLC | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Aukerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.